Ruvim Izĭckson discusses the safety and immunogenicity of administering a high-dose quadrivalent influenza vaccine together with a third dose of the Moderna COVID-19 vaccine in adults aged 65 years and older.
Read the full article:
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 year
Continue this conversation on social!
Follow us today at...